Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies - Concepedia

Concepedia

Publication | Open Access

Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies

DOI Full Paper Access

183

Citations

23

References

2021

Year

Stephen M. Ansell, Michael B. Maris, Alexander M. Lesokhin, Robert W. Chen, Ian W. Flinn, Ahmed Sawas, Mark D. Minden, Diego Villa, Mary‐Elizabeth M. Percival, Anjali S. Advani,

Clinical Cancer Research

Abstract

TTI-621 was well-tolerated and demonstrated activity as monotherapy in patients with R/R B-NHL and T-NHL and combined with rituximab in patients with R/R B-NHL.

References

	Year	Citations

Page 1